trial · primary record
Cilta-cel
Multiple Myeloma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 11 |
| Primary completion | 2027-08-26 |
| Primary endpoint | Number of Participants With Adverse Events (AE) by Severity According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 |
| Registry ID | NCT06550895 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:47.122Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06550895
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Cilta-cel · compound